A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC). A study of the PMH Phase II Consortium

BACKGROUND: GTI-2040, an antisense oligonucleotide, targets the ribonucleotide reductase R2 subunit, critical for DNA synthesis. This study determined the recommended phase 2 dose (RP2D) of docetaxel plus GTI-2040, toxicity, and response rate in advanced NSCLC. PATIENTS AND METHODS: Advanced solid t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Leighl, NB, Laurie, SA, Chen, XE, Ellis, P, Shepherd, FA, Knox, JJ, Goss, G, Burkes, RL, Pond, GR, Dick, C, Yen, Y, Zwiebel, JA, Moore, MJ
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2735463/
https://ncbi.nlm.nih.gov/pubmed/19704337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181a949b2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados